Maintrac® CTC Count Test
The Maintrac CTC Count test is a simple blood test finds every Circulating Tumour Cell present in the blood. CTCs in a 15-20mL sample of patient blood are detected and quantified. Live cells are distinguished from fragmented tumour cells and analysed. CTC-count is an independent prognostic indicator, that is, it gives an indication of the aggressiveness of a patient's cancer at the time of the test. A single CTC count test is intended as a simple baseline count. The best way to monitor cancer activity and long-term effectiveness of treatment is via a single CTC Count test every 3-6 months. Patient information hand-outs for your clinic are available upon request by contacting your local distributor.
CTC Count Test
Newly added publication: Behaviour of Circulating Epithelial Tumor Cells (CETCs) and FISH (Fluorescence In Situ Hybridization) of Epiderman Growth Factor Receptor (EGFR)-gene amplification in lung cancer patients during the course of therapy ...Read this publication
Publication: Epithelial cell dissemination and readhesion: Analysis of factors contributing to metastasis formation in breast cancer (2012) ...Read this publication
Publication: An increase in cell number at the completion of therapy may develop as an indicator of early relapse (2008) ...Read this publication
Publication: Monitoring Circulating Epithelial Tumour Cells (CETC) to gauge therapy: in patients with disease progression after tratsuzumab persisting CETC can be eliminated by combined lapatinib treatment (2008) ...Read this publication
Publication: Assessing the efficacy of targeted therapy using Circulating Epithelial Tumor Cells (CETCs): the example of SERM therapy monitoring as a unique tool to individualise therapy (2010) ...Read this publication
Maintrac® is a state-of-the-art German technology that detects, characterises and tests CTCs. It has been critically validated and published in peer reviewed journals for over 12 years. Maintrac® CTC tests are acknowledged and utilised by many universities, Oncologists and cancer clinics worldwide.